Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw an uptick in trading volume on Monday . 32,014 shares changed hands during trading, a decline of 56% from the previous session’s volume of 72,870 shares.The stock last traded at $13.05 and had previously closed at $12.84.
Gyre Therapeutics Stock Up 11.8 %
The firm has a 50 day moving average of $12.23 and a 200-day moving average of $14.38.
Insider Buying and Selling
In related news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the transaction, the director now owns 1,636 shares in the company, valued at approximately $19,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.92% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Gyre Therapeutics
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
- Five stocks we like better than Gyre Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- Investing in Construction Stocks
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.